Susquehanna International Group, LLP Cardiff Oncology, Inc. Transaction History

Susquehanna International Group, LLP

$568 Billion
Q1 2025

A detailed history of Susquehanna International Group, LLP transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 378,445 shares of CRDF stock, worth $1.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

378,445

Previous 258,642 46.32%

Holding current value

$1.18 Million

Previous $1.12 Million 5.88%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$3.14 - $4.75 $376,181 - $569,064	119,803 Added 46.32%	378,445 $1.19 Million
Q4 2024 Feb 14, 2025	BUY	$2.31 - $5.35 $597,463 - $1.38 Million	258,642 New	258,642 $1.12 Million
Q2 2024 Aug 15, 2024	SELL	$2.22 - $5.89 $104,968 - $278,496	-47,283 Reduced 56.79%	35,970 $79,000
Q1 2024 May 07, 2024	BUY	$1.46 - $5.91 $88,289 - $357,389	60,472 Added 265.45%	83,253 $444,000
Q4 2023 Feb 14, 2024	SELL	$0.96 - $1.55 $55,095 - $88,956	-57,391 Reduced 71.58%	22,781 $33,000
Q3 2023 Nov 14, 2023	SELL	$1.38 - $2.18 $19,778 - $31,243	-14,332 Reduced 15.17%	80,172 $111,000
Q2 2023 Aug 11, 2023	SELL	$1.37 - $1.95 $134,258 - $191,098	-97,999 Reduced 50.91%	94,504 $138,000
Q1 2023 May 16, 2023	BUY	$1.45 - $2.09 $14,676 - $21,154	10,122 Added 5.55%	192,503 $317,000
Q4 2022 Feb 14, 2023	SELL	$1.22 - $1.66 $28,532 - $38,822	-23,387 Reduced 11.37%	182,381 $255,000
Q3 2022 Nov 14, 2022	SELL	$1.54 - $3.21 $174,372 - $363,465	-113,229 Reduced 35.5%	205,768 $317,000
Q2 2022 Aug 15, 2022	BUY	$1.17 - $2.61 $254,873 - $568,565	217,841 Added 215.35%	318,997 $702,000
Q1 2022 May 16, 2022	SELL	$2.11 - $7.25 $327,062 - $1.12 Million	-155,006 Reduced 60.51%	101,156 $251,000
Q4 2021 Feb 14, 2022	BUY	$5.18 - $7.24 $292,804 - $409,248	56,526 Added 28.31%	256,162 $1.54 Million
Q3 2021 Nov 15, 2021	BUY	$5.01 - $7.58 $315,504 - $477,350	62,975 Added 46.08%	199,636 $1.33 Million
Q2 2021 Aug 11, 2021	SELL	$6.65 - $10.04 $1.49 Million - $2.24 Million	-223,488 Reduced 62.05%	136,661 $909,000
Q1 2021 May 17, 2021	BUY	$9.1 - $19.57 $1.02 Million - $2.2 Million	112,348 Added 45.34%	360,149 $3.34 Million
Q4 2020 Feb 16, 2021	BUY	$12.02 - $24.71 $2.98 Million - $6.12 Million	247,801 New	247,801 $4.46 Million

Others Institutions Holding CRDF

# of Institutions

124

Shares Held

29M

Call Options Held

900K

Put Options Held

234K

View Full List

About Cardiff Oncology, Inc.

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $136M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

More about CRDF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Cardiff Oncology, Inc. Transaction History